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Abstract
Background Integration of depression screening into primary care may increase access to mental health
services in sub-Saharan Africa, but this approach requires validated screening instruments. We sought to
validate the Patient Health Questionnaire-9 (PHQ-9) as a depression screening tool at a high HIV-burden
primary care clinic in Johannesburg, South Africa. Methods We conducted a validation study of an
interviewer-administered PHQ-9 among 397 patients. Sensitivity and specificity of the PHQ-9 were
calculated with the Mini International Neuropsychiatric Interview (MINI) as the reference standard; receiver
operating characteristic (ROC) curve analyses were performed. Results The prevalence of depression was
11.8%. One-third of participants tested positive for HIV. HIV-infected patients were more likely to be
depressed (15%) than uninfected patients (9%; p=0.08). Using the standard cutoff score of ¿10, the PHQ-9
had a sensitivity of 78.7% (95% CI: 64.3-89.3) and specificity of 83.4% (95% CI: 79.1-87.2). The area under
the ROC curve was 0.88 (95% CI: 0.83-0.92). Test performance did not vary by HIV status or language. In
sensitivity analyses, reference test bias associated with the MINI appeared unlikely. Limitations We were
unable to conduct qualitative work to adapt the PHQ-9 to this cultural context. Conclusion This is the first
validation study of the PHQ-9 in a primary care clinic in sub-Saharan Africa. It highlights the potential for
using primary care as an access point for identifying depressive symptoms during routine HIV testing. The
PHQ-9 showed reasonable accuracy in classifying cases of depression, was easily implemented by lay health
workers, and is a useful screening tool in this setting.
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INTRODUCTION
Mental illness imposes an immense global disease burden, particularly in low and middle-
income countries where access to mental health services is lacking (Kessler et al., 2009, 
Becker and Kleinman, 2013). Major depressive disorder (MDD) is the second leading 
contributor to years lived with disability (YLD) globally, and ranks within the top four 
causes of YLDs in all regions worldwide (Vos et al., 2012). In sub-Saharan Africa more 
than two-thirds of patients with severe mental illness are unable to access mental health care 
and this number rises to approximately 80% for patients with moderate or mild mental 
illness (Wang et al., 2007). To address these challenges, the integration of mental health 
screening approaches in primary care has been suggested as a mode for increasing access to 
care in low and middle-income settings (Collins et al., 2013, Tomlinson et al., 2009b).
The implementation of routine mental health screening in sub-Saharan African primary 
health care (PHC) settings requires validated rapid screening instruments that can be easily 
administered by lay healthcare workers in busy clinics (Freeman et al., 2005, Becker and 
Kleinman, 2013). To our knowledge, brief depression screening tools have not been 
validated for a general PHC context in sub-Saharan Africa. A limited number of validation 
studies of depression screening tools have been conducted against diagnostic reference 
standards in sub-Saharan African settings, but these studies have varied in their choice of 
context, screening tool, and diagnostic measure, making the results difficult to apply to a 
PHC context. (Andersen et al., 2011, Akena et al., 2012a, Akena et al., 2012b, Pence et al., 
2012, Chishinga et al., 2011, Monahan et al., 2009, Myer et al., 2008, Nakimuli-Mpungu et 
al., 2012b, Spies et al., 2009, Adewuya et al., 2006, Akena et al., 2013). In particular, the 
populations included in these studies, such as university students, household survey 
participants, pregnant or postnatal women, or HIV-infected patients, are not easily 
generalizable to a PHC population.
Depression is a common and debilitating comorbidity of HIV in sub-Saharan Africa. The 
reported prevalence of depression in HIV-infected African adults in ranges from 8–60%, 
several times greater than prevalence estimates in the general population (Ramirez-Avila et 
al., 2012, Hughes et al., 2004, Kagee and Martin, 2010, Myer et al., 2008, Olley et al., 2004, 
Lawler et al., 2011, Kinyanda et al., 2011, Nakimuli-Mpungu et al., 2011, Nakimuli-
Mpungu et al., 2012a, Tomlinson et al., 2009a). The relationship between MDD and HIV is 
complex, as depression can be a risk factor for HIV acquisition as well as a consequence of 
HIV infection (Smit et al., 2006, Simoni et al., 2011). However, MDD has long been 
recognized as a predictor of negative clinical outcomes among people with HIV (Bing et al., 
2001, Simoni et al., 2011, Owe-Larsson et al., 2009, Lopes et al., 2012). Persons with 
depression initiate anti-retroviral treatment (ART) at lower CD4 counts than people without 
mental illness, and depressed patients are much less likely to adhere to ART than patients 
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who are not depressed (Tegger et al., 2008, Gonzalez et al., 2011, Nakimuli-Mpungu et al., 
2012a, Kaharuza et al., 2006).
Routine mental health screening in PHC settings, where most HIV-infected patients are 
diagnosed and seek regular care, might be a valuable approach to identify both HIV-infected 
and HIV-uninfected patients who require further mental health assessment. Routine 
depression screening is recommended for HIV infected patients in high-resource settings 
and can be an effective way to identify patients at risk for negative outcomes (Shacham et 
al., 2009, Schumacher et al., 2012, O’Connor et al., 2009). Depressed HIV-infected patients 
who receive treatment for mental health illness have improved ART adherence and 
increased quality of life (Yun et al., 2005, Elliott et al., 2002). As interventions to increase 
access to early ART are scaled up throughout sub-Saharan Africa and universal HIV 
counseling and testing (HCT) becomes the norm, integration of mental health services and 
HIV programs could be an important component of ensuring optimal care and treatment 
utilization for these two highly comorbid conditions (Stein et al., 2005).
Here, we have conducted a validation study of an interviewer-administered brief screening 
tool for depression, in a high HIV burden, low literacy PHC population in Johannesburg, 
South Africa. We sought to validate the PHQ-9 as a depression screening tool compared to 
the internationally validated Mini International Neuropsychiatric Interview (MINI) among 
patients undergoing routine HCT in a primary care setting. We also sought to provide 
additional evidence of the utility of the PHQ-9 among HIV-infected people in sub-Saharan 
Africa.
METHODS
Ethical approvals
The Institutional Review Board at the University of North Carolina (No. 12–1730) and the 
Human Research Ethics Committee at the University of Witwatersrand (No. M120725) 
approved this study.
Study setting and population
Witkoppen Health and Welfare Centre (WHWC) is a high-volume primary health care clinic 
in northern Johannesburg, South Africa that provides comprehensive services predominantly 
to persons living in densely populated peri-urban formal and informal settlements. At 
WHWC, every clinic client with an unknown HIV status or with a negative HIV test more 
than three months old routinely undergoes opt-out HCT.
The study population comprised a randomly selected subset of patients who were 
undergoing routine HCT at WHWC between September 2012 and April 2013. Participants 
were eligible for enrollment if they presented at WHWC for any reason, were at least 18 
years old, not pregnant by self-report, could communicate in one of 5 common languages 
used by interviewers (English, isiZulu, isiXhosa, seSotho, seTswana), and were able to 
provide informed consent. Persons found to be experiencing acute suicidal ideation during 
the PHQ-9 were excluded and referred for immediate assistance.
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Measures
PHQ-9—The PHQ-9 is a 9-item depression screening tool that determines the presence and 
frequency of the 9 core depressive symptoms identified in the DSM-IV over the previous 2 
weeks. This tool has been widely utilized in Western settings and more recently in sub-
Saharan Africa (Pence et al., 2012, Monahan et al., 2009, Adewuya et al., 2006, Akena et 
al., 2013). Scores range from 0–27, with a score of 10 or higher typically used to indicate the 
presence of a depressive disorder that would benefit from treatment. While the PHQ-9 was 
developed to be self-administered, interviewer-administration has yielded similar results 
(Pinto-Meza et al., 2005).
MINI—The MINI International Neuropsychiatric Interview (MINI) is a short, structured 
diagnostic interview for major psychiatric disorders. The MINI served as the reference 
standard in this study (Sheehan et al., 1998). The MINI is a reliable and valid diagnostic tool 
that has been used successfully in South African populations (Myer et al., 2008, Olley et al., 
2004). We used the MINI modules for major depressive disorder (MDD), anxiety disorders 
(generalized anxiety disorder, panic disorder, social anxiety disorder, post-traumatic stress 
disorder), suicidality, and bipolar disorder.
Study Procedures
Eligible patients were selected randomly for recruitment each day. Patients were recruited 
after clinic registration but prior to undergoing HCT. After providing informed consent, the 
patient completed the screening interview, including the PHQ-9, with a trained lay-
interviewer. Questions about substance abuse and knowledge of HIV status (from prior 
testing experiences) were also included in the questionnaire. Socio-demographic information 
and clinical information was obtained from the patient’s WHWC clinic file. Due to low 
literacy in the study population, the questionnaire was administered by the interviewer and 
responses were recorded on a paper form. The questionnaire was translated and conducted in 
5 common languages (English, isiZulu, isiXhosa, seSotho, seTswana).
After the screening interview, participants immediately completed the MINI interview with 
a second study team member who was blinded to the results of the PHQ-9. The MINI 
interview was conducted by health care professionals trained in use of the instrument. The 
MINI was administered in the same language as the screening interview; an interpreter was 
used when needed. Translations of the MINI were completed in the same languages used for 
the screening tools and these standard translations were used when needed.
Study data were collected and managed using Research Electronic Data Capture (REDCap) 
tools hosted at the University of North Carolina, Chapel Hill (Harris et al., 2009).
Analyses
A positive screen for probable depression was defined as a score ≥10 on the PHQ-9 (Pence 
et al., 2012, Adewuya et al., 2006, Akena et al., 2013). Test characteristics including 
sensitivity, specificity, and categorical likelihood ratios for the PHQ-9 were calculated 
relative to a diagnosis of a current major depressive episode (MDE) on the MINI. A range of 
cut-off scores (Data presented for cut-off scores of 8, 10, and 12) was considered for the 
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PHQ-9. Categorical likelihood ratios were calculated for the standard scores of ≥5 (mild 
depression/anxiety), ≥ 10 (moderate depression/anxiety), ≥ 15 (moderately severe 
depression/severe anxiety), and ≥20 (severe depression). Post-test probabilities (analogous 
to positive predictive values for a dichotomous test) were calculated for a range of 
prevalence values of depression using categorical likelihood ratios. Receiver operating 
characteristic (ROC) plots were graphed and the area under the curve (AUC) is reported. 
Sensitivity analysis was conducted to assess the possible bias in PHQ-9 test performance 
produced by misclassification of MDE by the MINI. Varying combinations of sensitivity 
and specificity of the MINI reference standard were considered. In conditional independence 
scenarios, which did not assume any relationship between a patient’s score on the PHQ-9 
and their score on the MINI, MINI sensitivity was varied from 0.75 to 1.00 and specificity 
from 0.97 to 1.00. In conditional dependence scenarios, it was theorized that patients who 
underreported depressive symptoms on the PHQ-9 might also underreport on the MINI. For 
the conditional dependence assessments, a range of reduced sensitivities of the MINI was 
considered for the population who screened negative on the PHQ-9. Stata version 12 
(College Station, TX) was used for all analyses.
RESULTS
Between September 2012 and April 2013, 397 persons provided informed consent to 
participate in this study. Participants had a median age of 35 years (IQR: 28–46 years) and 
most were female (60%). About half of the participants were from South Africa (48%) and 
more than a third were from Zimbabwe (37%). Nearly 60% were employed and 30% 
reported drinking alcohol (Table 1). Of the 397 participants, 257 (64.7%) tested negative for 
HIV on the enrollment date or within the previous 2 weeks and 113 (28.5%) tested positive 
at enrollment or were not tested because they told the HIV counselor that they knew their 
positive status and were enrolled in HIV care at another clinic (n=9). About two-thirds of 
patients (65%) rated their general health status as good, very good, or excellent, while the 
remainder reported poor or fair health. Compared to patients who were not depressed, 
patients with depression reported poor or fair health more often (p<0.0001) and were more 
likely to be female (p=0.06) and HIV-infected (p=0.08). Other demographic characteristics 
were similar among depressed and not depressed patients. According to the PHQ-9, 44% of 
the participants reported no depression (PHQ9= 0–4), 32% reported mild depression 
(PHQ9=5–9), 18% reported moderate depression (PHQ9=10–14), 5% reported moderately 
severe depression (PHQ9=15–19), and 1% reported very severe depression (PHQ9≥20).
PHQ-9
Of the 397 persons completing the MINI, 47 (11.8%) met the diagnostic criteria for a current 
MDE on the MINI. Of the 47 patients, 19 (40.4%) were experiencing a comorbid anxiety 
disorder and 3 (0.76%) met criteria for bipolar spectrum disorder. The most common 
comorbid anxiety disorders were generalized anxiety disorder (GAD) and post-traumatic 
stress disorder (PTSD). Compared to the MINI, the PHQ-9 performed modestly in this 
population. Of the 47 persons meeting criteria for MDE, 37 had a positive PHQ-9 
depression screen with the standard cut-off score of 10 or higher, yielding a sensitivity of 
78.7% (95% CI: 64.3–89.3) (Table 2). Of the 350 participants who did not meet criteria for 
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current major depression on the MINI, 292 had a negative depression screen on the PHQ-9, 
corresponding to a specificity of 83.4% (95% CI: 79.1–87.2). An alternate PHQ-9 cut-off 
score of 8 in the overall sample yielded a higher sensitivity of 87.2% (95% CI: 74.3–95.2) 
and a lower specificity of 73.4% (95% CI: 68.5–78.0). A higher alternate cut-off score of 12 
yielded a lower sensitivity of 55.3% (95% CI: 40.1–69.8) and a higher specificity of 89.1% 
(95% CI: 85.4–92.2).
In ROC analysis, the PHQ-9 had an area under the curve (AUC) of 0.88 (95% CI: 0.83–
0.92), indicating moderately high accuracy (Figure 1). Likelihood ratios for the commonly 
used PHQ-9 categories representing mild (5–9), moderate (10–14), moderately severe (15–
19), and severe (20–27) depression were 0.09, 0.50, 3.89, 6.77, and 22.3 respectively (Table 
3). Post-test probabilities for these categories were calculated for a range of pre-test 
probability (prevalence) values (Figure 2). At the 11.8% prevalence of MDE seen in the 
study population (indicated by vertical line, Figure 2), the post-test probability of depression 
for a PHQ-9 score between 10–14 is 34.2%, for a score between 15–20 it is 47.5%, and for a 
score higher than 20 it is 75%.
Among HIV-positive participants, 15.0% (n=17) met the criteria for MDE compared to 
8.9% of the HIV-negative participants. The PHQ-9 performed similarly in the HIV-positive 
and HIV-negative populations (Table 2). Among the 113 HIV-infected patients, the PHQ-9 
yielded a slightly higher sensitivity and a lower specificity compared to the HIV-negative 
population, although these estimates are imprecise as there were only 17 cases of MDE in 
the HIV-infected group.
Misclassification of true MDE by the MINI was not likely to have produced substantial bias, 
as shown by sensitivity analyses. All scenarios where conditional independence was 
considered suggested that the true values of sensitivity and specificity of the PHQ-9 were 
underestimated by the observed estimates. Corrected estimates for sensitivity of the PHQ-9 
ranged from 0.84 to 0.99 and corrected estimates for specificity of the PHQ-9 ranged from 
0.84 to 0.86. Conditional dependence, assessed by reducing the sensitivity of the MINI for 
patients screening negative on the PHQ-9, only slightly changed the observed results. 
Additionally, the performance of the PHQ-9 did not differ according to the language in 
which the interview was conducted.
DISCUSSION
In this high HIV burden PHC population in Johannesburg, South Africa, the PHQ-9 showed 
high accuracy in correctly classifying cases of current MDE (AUC 0.88) relative to the 
reference standard MINI. At the standard cut-off score of 10, the PHQ-9 had moderately 
high sensitivity and specificity in the study population. The performance of the PHQ-9 was 
similar to that from a range of other settings outside of sub-Saharan Africa (Gilbody et al., 
2007, Manea et al., 2012). Compared to other studies within sub-Saharan Africa, the PHQ-9 
performed slightly worse than it did among university students in Nigeria (Adewuya et al., 
2006) or HIV-infected persons in Uganda (Akena et al., 2013), but it performed significantly 
better in this study than it did among HIV-infected patients in Cameroon (Pence et al., 
2012). To our knowledge, ours is the only diagnostic validation study of the PHQ-9 
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conducted among a general PHC population in sub-Saharan Africa, and it underscores both 
the importance of a primary care setting in this region as an access point for identifying 
depression and as well an accurate tool to do so.
We found an 11.8% prevalence of MINI-defined current MDE in the overall study sample, 
higher than previously found among the general population in South Africa. A nationally 
representative household survey found that 4.9% of South Africans had suffered from MDE 
in the previous 12 months, as measured by the World Health Organization’s (WHO) 
Composite International Diagnostic Interview (CIDI) (Tomlinson et al., 2009a). We would 
expect our estimate to be higher than the prevalence from a household survey as our sample 
includes chronically ill and disenfranchised patients who are more likely to experience 
mental illness.
The variation between our prevalence estimate and others from the region may also be 
explained by other estimates deriving from differing screening instruments, some of which 
have not been validated against diagnostic tools. Additionally, some other prevalence 
estimates focus particularly on specific population subsets rather than the general 
population. For example, among the HIV-infected subset of this population, depression 
prevalence was 15%, comparable to other prevalence estimates of MDD among HIV-
infected African persons in studies using diagnostic tools (range ~3–35%) (Adewuya et al., 
2006, Lawler et al., 2011, Nakimuli-Mpungu et al., 2012b, Myer et al., 2008, Akena et al., 
2013, Spies et al., 2009). The high prevalence of comorbid anxiety disorders, particularly 
GAD and PTSD, among depressed patients in this population reiterates the need to assess 
patients presenting with depressive symptoms for comorbid psychiatric diagnoses, which 
can lead to increased psychiatric severity and treatment resistance (Kessler et al., 2005, 
Gaynes et al., 1999).
When evaluating the clinical utility of the PHQ-9 for depression screening and choosing an 
ideal cut-off score for this setting, we considered the prevalence of depression in the 
population, the benefits and harms of screening, and the resources available for screening 
and follow-up. In our study context, a busy PHC clinic in a resource-scarce setting with one 
part-time mental health professional, patients screened by lay-workers using the PHQ-9 
would then be evaluated by a PHC clinician who could confirm that a clinical depression 
exists and decide whether to begin treatment in the PHC setting or refer to a mental health 
professional. In this scenario, the categorical likelihood ratios, which capture the magnitude 
of depression, are particularly useful in prioritizing patients compared to the standard 
dichotomous cut-off score alone. The standard score of 10 groups together all patients with a 
score of 10 or higher-so those who have a score of 11 (moderate depression) and those who 
have a score of 20 (severe depression) are considered the same, discarding valuable 
information about the degree of illness. In contrast, the categorical likelihood ratios allow 
the clinician to prioritize patients based on the magnitude of the depression score and the 
post-test probability of disease for a particular value of the PHQ-9. By multiplying the 
categorical likelihood ratio for a particular score by the pre-test odds of disease, a post-test 
odds can be calculated and easily converted to a post-test probability (Sonis, 1999). A 
patient with a PHQ-9 score of 11 at WHWC has a post-test probability of approximately 
34% of being depressed as compared to a post-test probability of approximately 75% for a 
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patient with a PHQ-9 score of 20. Using the categorical likelihood ratios would allow these 
two patients with different likelihoods of depression to be prioritized accordingly for the 
limited mental health resources available at WHWC. The categorical likelihood ratios also 
allow decision-makers to adjust the pre-test probability value for different groups of patients 
by taking into account factors such as medical history (e.g. HIV infection status) or 
laboratory data, rather than only the overall prevalence of depression in the general clinic 
population. In this more sophisticated approach, one standard cutoff score is not applicable 
to all patients in a clinic, but rather the cutoff score differs depending on a number of 
important variables specific to each patient.
In choosing an ideal cut-off score for the PHQ-9, we also considered the relative cost of a 
false negative versus a false positive result. In our study setting, where many patients were 
coping with chronic diseases such as HIV, it might be reasonable to consider a false 
negative, or missing a true case of depression, to be worse than a false positive. Patients with 
chronic conditions and comorbid depression are at risk for a multitude of negative outcomes 
including poor adherence to treatment and increased morbidity and mortality (Katon, 2011). 
Therefore, identifying the maximum number of true depression cases might be considered a 
priority, especially among HIV infected patients in whom treatment initiation and adherence 
is a significant concern. This approach would come at the expense of a higher number of 
false positive screens, creating a higher burden on the clinic to spend time and resources 
evaluating patients who are not true depression cases. These choices are ultimately 
dependent on the setting in which the tool is applied and the resources available for follow-
up.
The strengths and limitations of this study should be considered. The cultural construct of 
depression or anxiety in our study setting is likely to be very different from the Western 
settings in which the PHQ-9 was first developed. The version of the PHQ-9 used in this 
study was the same as that used in Cameroon among HIV-infected patients, which had been 
adapted slightly through focus group feedback in Cameroon (Pence et al., 2012). While we 
were able to translate the PHQ-9 into local languages, we were unable to conduct additional 
focus groups or qualitative interviews in our study setting that would have allowed us to 
further adapt the PHQ-9 for culturally-relevant use in this context and ensure that the tool 
was well understood by the study population. Although our results did not differ according 
to the language in which the PHQ-9 was administered, such qualitative research might have 
increased the diagnostic properties of the PHQ-9 in our study. We would encourage other 
researchers to conduct preliminary qualitative work when adapting and optimizing screening 
tools for use outside of the context in which the tool was originally developed and validated.
While the MINI was used as the reference standard in our study, it is imperfect, especially in 
light of the cultural considerations discussed above. However, the MINI has been validated 
against other diagnostic interviews, including the CIDI and the Structured Clinical Interview 
for DSM Disorders (SCID) and has itself been used as a reference standard for the validation 
of many other psychiatric scales (Sheehan et al., 1998). Misclassification or reference-test 
bias with use of the MINI is likely to occur to some degree, and will depend partly on the 
experience level of the interviewer. Given the rigorous DSM-IV criteria utilized in the 
MINI, we believe that false positives will be rare, although false negatives or missing cases 
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of true MDE is possible. This would have biased our measured estimates of PHQ-9 
sensitivity and specificity downwards. Our sensitivity analyses were consistent with 
observed estimates of sensitivity and specificity of the PHQ-9 being underestimated. Given 
our observed data, a MINI specificity of anything less than 1 would suggest that the reported 
sensitivity of the PHQ-9 is an underestimate of the true sensitivity. Our data were 
inconsistent with a MINI specificity less than 0.97 because of the low number of MDE cases 
among patients screening negative on the PHQ-9. An additional source of bias could have 
arisen through interviewer-administration of the PHQ-9 as participants may be less likely to 
report mental health symptoms to an interviewer due to fear of stigmatization. This could 
lead to conditional dependence through lower sensitivity of the MINI among patients who 
screen negative on the PHQ-9, but sensitivity analysis showed that this would only slightly 
affect our observed estimates of PHQ-9 performance.
Mental health screening in this study was conducted among patients prior to undergoing 
HCT. The advantage to this approach is that it allowed us to evaluate the performance of 
screening instruments among patients who were HIV-negative as well as the 28.5% of the 
study population who tested HIV positive after their participation in this study. Because 
patients received their HIV test results after depression screening, new knowledge of an HIV 
diagnosis would not have influenced HIV infected patients to screen positive for depression 
due to an acute adjustment disorder with a depression reaction. We recognize that the HIV-
infected patients in this population are different from those engaging in ongoing HIV care 
who have been coping with long-term knowledge of HIV status, and that the prevalence of 
mental illness may differ at various time points in HIV care. Other research on depression 
and HIV in sub-Saharan Africa has focused mostly on patients who are aware of their HIV 
status rather than those who are testing for HIV. Our results contribute important 
information to the field as the mental health of HIV-infected patients prior to HCT has not 
been evaluated. Identifying patients with underlying depression as early as HCT could help 
identify patients at risk of defaulting treatment or care early on. Ideally, we would screen 
patients for mental health illness at several time points in HIV care, if resources for follow-
up exist.
The PHQ-9 performed reasonably well as a screening tool in this high HIV-burden South 
African clinic population and was easily implemented by lay health workers. Our results 
provide insight on how we can screen for and prioritize often overlooked and highly 
prevalent depressive symptoms in low-resource PHC settings in sub-Saharan Africa. Such 
an intervention might be especially useful for monitoring high-risk subsets of the population 
such as HIV-infected people at risk for defaulting treatment, although further research will 
be required to determine how screening for depression can contribute to improved clinical 
outcomes. This study provides a framework for implementing depression screening 
programs in resource-scarce sub-Saharan African contexts and establishes the PHQ-9 as a 
useful screening instrument in these settings.
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Figure 1. 
Receiver operating characteristic (ROC) curve for PHQ-9
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Figure 2. 
Post-test probability for varying PHQ-9 categories, based on categorical likelihood ratios.
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Table 1
Characteristics of the study population by depression (N=397)
Characteristic Total study population* Depression n (%) or median (IQR)
(n=397) Yes (n=47) No (n=350)
Age (years)
 <=25 59 (14.9) 4 (8.5) 55 (15.7)
 26–35 147 (37.0) 20 (42.6) 127 (36.3)
 36–45 87 (21.9) 10 (21.3) 77 (22.0)
 46–55 71 (17.9) 10 (21.3) 61 (17.4)
 >55 33 (8.3) 3 (6.4) 30 (8.6)
Gender
 Male 159 (40.1) 13 (27.7) 146 (41.7)
 Female 236 (59.5) 34 (72.3) 202 (57.7)
Employment status
 Employed 230 (63.7) 29 (65.9) 201 (63.4)
 Unemployed 131 (36.3) 15 (34.1) 116 (36.6)
Country of birth
 South Africa 190 (49.9) 27 (57.4) 163 (48.8)
 Other country 191 (50.1) 20 (42.6) 171 (51.2)
Alcohol use
 Any 118 (30.0) 13 (28.3) 105 (30.2)
 None 276 (70.1) 33 (71.7) 243 (69.8)
Perceived health status
 Excellent 60 (15.2) 6 (13.0) 54 (15.5)
 Very good 57 (14.5) 4 (8.7) 53 (15.2)
 Good 139 (35.3) 10 (21.7) 129 (37.1)
 Fair 79 (20.1) 13 (28.3) 66 (19.0)
 Poor 59 (15.0) 13 (28.3) 46 (13.2)
HIV status
 Positive 113 (28.5) 17 (36.2) 96 (27.4)
 Negative 257 (64.7) 23 (48.9) 234 (66.9)
 Unknown† 27 (6.8) 7 (14.9) 20 (5.7)
*
Categories may not sum to the total because of missing data
†
Twenty seven participants are of unknown HIV status because they were either: 1) found to be either suicidal or mentally distressed during this 
study so HCT was deferred (n=5, 1.3%); 2) they refused to test for HIV after undergoing pre-test counseling (n=6, 1.5%); or 3) the patient skipped 
HCT (n= 16, 4%).
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Table 3
Likelihood ratios for commonly used PHQ-9 decision thresholds
Symptom severity PHQ-9 category Likelihood ratio
No depression ≤5 0.09
Mild depression 5–9 0.50
Moderate depression 10–14 3.89
Moderately severe depression 15–19 6.77
Severe depression 20–27 22.3
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